1Hormones Department, Medicine and Clinical Studies Research Institute, National Research Centre, Cairo, Egypt.
Stem Cell Lab, Center of Excellence for Advanced Sciences, National Research Centre, Dokki, Giza, P.O 12622, Egypt.
Asian Pac J Cancer Prev. 2022 Dec 1;23(12):4261-4274. doi: 10.31557/APJCP.2022.23.12.4261.
Hepatocellular carcinoma (HCC) microenvironment has been recognized as a key contributor for cancer progression, metastasis, and drug resistance. The crosstalk between tumor cells, the vascular endothelial growth factor (VEGF), and the chemokine (C-C motif) ligand 2 (CCL2) signaling networks mediates immunoinhibitory impact and facilitates tumor angiogenesis. The current investigation aimed at exploring the potent anti-cancer activity of the newly designed nano-based anti-cancer therapy comprising anti-VEGF drug, avastin (AV), and CCR2 antagonist (CR) to counteract HCC and tracking its mode of action in vivo.
The prepared AV, CR, and AVCR nanoprototypes were characterized by nanoscale characterization techniques in our previous work. Here, they are applied for unearthing their anti-cancer properties / mechanisms in hepatic cancer-induced rats via analyzing protein levels and genetic expression of the elements incorporated in the angiogenesis, apoptosis, and metastasis signalling pathways.
The present results revealed a significant down-regulation in the angiogenesis, survival and metastasis indices along with up-regulation in the pro-apoptotic mediators upon treatment of hepatic cancer-bearing rats with the novel synthesized nanomaterials when compared with the untreated counterparts. We showed across HCC model that anti-VEGF in combination with CCR2 antagonism therapy leads to sensitization and enhanced tumor response over anti-VEGF or CCR2 antagonism monotherapy, particularly in its nanoscale formulation.
The present approach provides new mechanistic insights into the powerful anti-hepatic cancer advantage of the novel nanoprototypes which is correlated with modulating critical signal transduction pathways implicated in tumor microenviroment such as angiogenesis, apoptosis and metastasis. This research work presents a substantial foundation for future studies focused on prohibiting cancer progression and recovery by targeting tumor microenviroment.
肝细胞癌 (HCC) 微环境已被认为是癌症进展、转移和耐药的关键因素。肿瘤细胞、血管内皮生长因子 (VEGF) 和趋化因子 (C-C 基序) 配体 2 (CCL2) 信号网络之间的串扰介导免疫抑制作用,并促进肿瘤血管生成。本研究旨在探索新设计的基于纳米的抗癌疗法的强大抗癌活性,该疗法包括抗 VEGF 药物阿瓦斯汀 (AV) 和 CCR2 拮抗剂 (CR),以对抗 HCC 并在体内追踪其作用模式。
在我们之前的工作中,通过纳米级表征技术对制备的 AV、CR 和 AVCR 纳米原型进行了表征。在这里,它们被应用于通过分析纳入血管生成、凋亡和转移信号通路的元素的蛋白质水平和遗传表达,来挖掘它们在肝癌诱导大鼠中的抗癌特性/机制。
与未治疗的对照组相比,用新型合成纳米材料治疗肝癌荷瘤大鼠后,发现血管生成、存活和转移指数显著下调,同时促凋亡介质上调。我们在 HCC 模型中表明,抗 VEGF 联合 CCR2 拮抗疗法导致对肿瘤的敏感性增加,并且比抗 VEGF 或 CCR2 拮抗单药疗法更能增强肿瘤反应,特别是在其纳米制剂中。
本研究为新型纳米原型在调节肿瘤微环境中涉及血管生成、凋亡和转移等关键信号转导通路方面具有强大的抗肝癌优势提供了新的机制见解。这项研究工作为未来通过靶向肿瘤微环境来阻止癌症进展和恢复提供了重要的基础。